Sanofi to Buy Vicebio for Up to $1.6 Billion in Vaccine Push

Sanofi agreed to buy UK biotech Vicebio Ltd. for as much as $1.6 billion, gaining experimental vaccines and a technology to streamline their development.

The French drugmaker will pay $1.15 billion upfront with a commitment for potential milestones worth as much as $450 million, it said in a statement Tuesday.